However, it may be that the introduction of new medications such as Glucagon-Like Peptide-1 (GLP-1) receptor agonists may change practice: the American Association of Clinical Endocrinologist guidelines emphasize this point with consideration of those patients who have not responded to intensive lifestyle therapy, or have experienced weight regain after responding to lifestyle therapy, and those with more severe complications of obesity [91]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.